Catalent - CTLT Stock Forecast, Price & News

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft cut their target price on Catalent from $129.00 to $110.00 and set a "hold" rating on the stock in a research note on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $142.86.

Catalent Stock Performance

Shares of CTLT opened at $110.56 on Monday. The firm has a market cap of $19.81 billion, a PE ratio of 40.06, a PEG ratio of 1.68 and a beta of 1.28. Catalent has a 1 year low of $86.34 and a 1 year high of $142.64. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The stock's fifty day moving average price is $107.32 and its two-hundred day moving average price is $103.03.

Insider Activity

In related news, CFO Thomas P. Castellano sold 347 shares of the company's stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $37,094.30. Following the sale, the chief financial officer now owns 15,051 shares in the company, valued at approximately $1,608,951.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Thomas P. Castellano sold 347 shares of the firm's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $37,094.30. Following the transaction, the chief financial officer now directly owns 15,051 shares of the company's stock, valued at approximately $1,608,951.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Steven L. Fasman sold 2,546 shares of the firm's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $272,167.40. Following the transaction, the executive vice president now owns 53,721 shares of the company's stock, valued at approximately $5,742,774.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,462 shares of company stock valued at $476,951. Insiders own 0.53% of the company's stock.